Aug 26, 2024｜2024
Henlius Maintains Patient-Centric Focus, Drives Sustainable Growth, and Accelerates Overseas Expansion in 2024 H1
Shanghai, China, August 26, 2024 – Henlius (2696.HK) announced its 2024 interim results. During the reporting period, Henlius’ revenue reached about RMB2.7461 billion, representing an increase of 9.8% YoY, and recorded a net profit of RMB386.3 million, up by 61.0% YoY. The solid and sustained profitability is due to increasing commercial sales of the company’s core products, which reached approximately RMB2.4794 billion. HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe) and HANSIZHUANG recorded sales of RMB1.4743 billion and RMB677.8 million, respectively. Meanwhile, the company accelerates the expansion of its global commercial footprint, unleashing the potential of overseas markets to promote its long-term high-quality development.
Up to date, Henlius has 6 products launched in China, 3 approved for marketing in overseas markets, 24 indications approved worldwide, benefiting over 600,000 patients and reaching 48 markets in Asia, Europe, Latin America, North America and Oceania. During the reporting period, the company submitted approximately 80 drug registrations, and received more than 60 approvals in China, the U.S., EU, Canada, Indonesia and Japan. Meanwhile, the company stays focused on differentiated innovation to accelerate the development of products in its pipeline. Currently, its product pipeline covers more than 50 molecules and 14 R&D platforms with the forms of drug covering mAb, pAb, antibody-drug conjugate (ADC), fusion protein, and small molecule drug, etc.
Wenjie Zhang, Chairman and Executive Director of Henlius, said:" In the first half of 2024, we have received impressive results based on our well-established commercial strategy and layout. Following the first time full-year profits in 2023, we achieved sustainable profitability and steady growth, opening a new chapter of high-quality development. Looking forward, we will further promote differentiated innovation and proactively respond to external changes. Meanwhile, we will continue to advance lean management and operations to solidify our leading position, progressing towards an innovative global biopharmaceutical company with a focus on high-quality development."
Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said:" Innovation and globalisation are two core strategies propelling us along the journey of addressing unmet clinical needs. In the first half of 2024, we have been actively expanding our global footprint with significant milestones achieved on our way of going abroad. Meanwhile, our innovation landscape has rapidly expanded, further strengthening our differentiated innovations. In the future, we will adhere to patient-centricity and stay committed to providing high-quality and innovative therapies to benefit more patients worldwide."
Global Expansion: Swift Overseas Commercialisation & Vast Market Opportunities
In the first half of 2024, Henlius continued to efficiently drive the integrated development of research, production, and commercialisation, while constantly improving commercial operational efficiency. Through multi-faceted measures such as improving product accessibility and exploring diversified business models, the company fostered the commercial growth of its core products, achieving sustained high-quality profitability. Furthermore, the company has achieved notable milestones in its global market expansion endeavors, with approvals and successful commercialisation across various markets infusing fresh momentum into the growth of its overseas presence. During the period, Henlius’ five products reached total sales revenue of approximately RMB2.4794 billion, up by 15.2% YoY. HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), HANSIZHUANG (serplulimab), and HANBEITAI (bevacizumab) recorded sales of RMB1.4743 billion, RMB677.8 million and RMB86.7 million, respectively. In addition, the company received sales revenues of RMB227.0 million and RMB13.6 million based on the collaboration with partners for HANLIKANG (rituximab) and HANDAYUAN (adalimumab), respectively.
Henlius' core oncology product HANQUYOU maintains a positive growth momentum. During the reporting period, HANQUYOU has recorded a global sales revenue of RMB1.4743 billion, up by 15.5% YoY. To date, HANQUYOU has been approved in 48 countries and regions around the world, covering Asia, Europe, Latin America, North America, and Oceania, making it the China-developed monoclonal antibody (mAb) biosimilar with the most marketing approvals, benefiting more than 200,000 patients. From which, HANQUYOU recorded domestic sales of RMB1.4062 billion, representing growth of 13.5%, further expanded its market share in China. Due to its differentiated clinical advantages and international recognised quality, HANQUYOU has been widely used in clinical practice and achieved rapid market acceptance, making it the leading brand of trastuzumab in China. Moreover, Henlius has proactively pursued overseas commercialisation of HANQUYOU, overseas revenue from product sales recorded RMB68.2 million approximately, up by 79.1% YoY. In April 2024, it received marketing approval from the U.S. Food and Drug Administration (FDA), making it a China-developed mAb biosimilar approved in China, the EU, and the U.S. In June 2024, HANQUYOU made its first delivery to Saudi Arabia，poised to be the first Chinese mAb to enter the Middle Eastern market. As of August 2024, the overseas commercialisation of HANQUYOU managed to include the markets of the U.S., Canada, the Philippines, Brazil, Uzbekistan and Turkmenistan, bringing more benefits to patients.
HANSIZHUANG is the world’s first anti-PD-1 mAb approved for the first-line treatment of small cell lung cancer (SCLC), has been launched in China, Indonesia, Cambodia and Thailand. During the reporting period, HANSIZHUANG has recorded a sales revenue of RMB677.8 million, representing an increase of 21.8% YoY. Up to now, it has been approved for 4 indications, broadly covering high-incidence tumours including lung cancer and gastrointestinal cancer, benefiting over 7,5000 patients. Additionally, the 5th NDA of HANSIZHUANG for the first-line treatment of non-squamous non-small cell lung cancer (nsNSCLC) has been accepted by the National Medical Products Administration (NMPA), and expected to be approved in the second half of 2024. On the other hand, overseas sales revenue and licensing of HANSIZHUANG recorded RMB75.2 million approximately. Henlius continues to expand HANSIZHUANG’s global footprint, which now covers more than 70 countries and regions including the U.S., Europe, Southeast Asia and MENA, making it the first China anti-PD-1 mAb successfully approved for marketing in Southeast Asia. In the first quarter of 2024, Henlius has finished the first international shipment of HANSIZHUANG, opening a new chapter in benefiting patients worldwide with this product. HANSIZHUANG’s Marketing Authorisation Application (MAA) for ES-SCLC has been validated by the European Medicines Agency (EMA), which is expected to be approved in 2024. The company has also submitted marketing applications for HANSIZHUANG in Singapore and Malaysia to further promote the product in Southeast Asia. Moreover, Henlius steadily advances a head-to-head bridging trial in the United States to compare HANSIZHUANG to standard of care atezolizumab (anti-PD-L1 mAb) for the first-line treatment of ES-SCLC, and plans to submit the Biologic License Application (BLA) of the product in the U.S. in early 2025.
In the first half of 2024, Henlius achieved a number of milestones in business development. Regarding HLX78 (lasofoxifene), the company expanded its collaboration with Sermonix in all of Asia. Additionally, Henlius reached cooperation with Convalife to commercialise neratinib (trade name: HANNAIJIA), which is indicated for extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy, further enriching the company’s product pipeline for breast cancer treatment and creating synergy with HANQUYOU. Meanwhile, the company joined hands with international partners such as Accord, Eurofarma, KGbio and Organon to accelerate overseas commercialisation of its products. In the first half of 2024, HANLIKANG, the first biosimilar launched in China, has been approved to be marketed in Peru, which made it the company’s third self-developed and manufactured product breaking into global markets. Furthermore, the marketing application for HLX14 (denosumab biosimilar) has been accepted for review in European Union (EU) in May 2024, and expected to be approved in 2025. The company also plans to submit marketing applications for HLX14 in the U.S., and for HLX11 (pertuzumab biosimilar) in China and the U.S. in the second half of 2024.
Synergistic Growth: Accelerating Innovation & Ensuring Manufacturing Meets International Quality Standards
In the first half of 2024, Henlius hase been continuously advancing its differentiated R&D pipeline with the vision of offering high-quality and affordable innovation products, proactively exploring novel modalities and diverse disease areas. Guided by unmet clinical needs, the company has accelerated the clinical researches of a number of innovative products including HANSIZHUANG (serplulimab), HLX22 (anti-HER2 mAb), HLX42 (EGFR-targeting ADC) and HLX6018 (anti- GARP/TGF-β1 mAb). During the reporting period, the phase 3 international multicenter clinical study (ASTRUM-015) of serplulimab in combination with bevacizumab and chemotherapy indicated for the treatment of metastatic colorectal cancer (mCRC) has been permitted by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and completed dosing of the first subject in China. Meanwhile, a phase 3 international multicenter clinical study of Henlius’ novel anti-HER2 mAb, HLX22, in combination with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric cancer has been approved by the U.S. FDA. The latest results for innovative products such as HANSIZHUANG and HLX22 have been presented to global academic community, including Cancer Cell, Med, AACR, ASCO, ASCO GI, ESMO GI, and ENCALS, gaining wide recognition. Moreover, the company has completed the first patient dosing for clinical trials of HLX42, the potential first/best-in-class EGFR-targeting ADC, and of HLX6018, the company’s first novel product in chronic inflammatory diseases area. In addition, the company has received the IND approval for the clinical trial of novel anti-TIGIT fc fusion protein HLX53 in combination with HANSIZHUANG plus HANBEITAI for the first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC) from the NMPA, and has completed the first patient dosing for a phase 2 clinical trial.
While boosting innovation, Henlius is steadily consolidating international high quality manufacturing capability to accelerate its global commercialisation layout, translating the R&D efforts into social impact and commercial results. The company currently has three manufacturing facilities: Shanghai Xuhui Facility, Songjiang First Plant and Songjiang Second Plant. Regarding Songjiang Second Plant, the company has completed construction and validation of drug substance (DS), drug product (DP) and prefilled syringes system (PFS) line of the two major manufacturing buildings in the Phase I & II project, and main structural framework was topped out in the Phase III project. Currently, the commercial capacity of the company is 48,000 litres, enabling stable supply to markets beyond China, including Europe, Southeast Asia, Latin America and Middle East. Additionally, the company has always been upholding the highest quality standards, allowing its products to go global. As of now, Henlius’ commercial production facilities and supporting quality management system have also passed nearly one hundred on-site inspections and audits conducted by the NMPA, the EMA, the FDA, the EU Qualified Person (QP), as well as Henlius’ international business partners, and have been GMP-certificated by China, the EU and U.S. regulatory agencies. The company also adopted a series of lean operation projects, optimised production processes, utilized digital technology to empower supply chain, inventory and quality management, putting "affordable innovation, trustworthy quality" into practice.
Focusing on patients unmet clinical needs, Henlius will further strengthen its commercialisation capabilities as a biopharma, improve the operation efficiency of its integrated biopharmaceutical platform, and expand its global presence, enabling high-quality innovative outcomes to benefit more patients worldwide.
Back
Privacy Policy
Cookies Policy
Accessibility
Terms of Use
Privacy Policy
Introduction
Shanghai Henlius Biotech, Inc., and, where applicable, its affiliates and subsidiaries (collectively, “we” , “us” or “our”) attach great importance to the protection of your privacy and personal information. This Privacy Notice (this “Policy”) is formulated in accordance with applicable PRC laws and regulations governing the protection of personal information in the People’s Republic of China (“PRC”).
This Policy applies when: (1) you browse or use our website and other online resources (such as our WeChat official accounts); (2) subscribe to our news or announcements; or (3) contact us through the contact details or other interactive features made available on our website, or otherwise interact with us through our website.. The purpose of this Policy is to explain how and why we process your personal information, the types of personal information involved, applicable retention periods, your rights, and the measures we take to protect personal information. Please read this Policy carefully to ensure that you fully understand its content.
In certain business scenarios, we may provide additional explanations regarding the processing of your personal information through separate agreements, privacy statements, or personal information notices. In the event of any inconsistency, such documents shall prevail. For example, where a recruitment function is provided through a third-party platform or service, the relevant third party privacy policy or notice may also apply.
For the purposes of this Policy, “personal information” refers to all kinds of information related to identified or identifiable natural persons, excluding anonymized information.
We collect, use, store, transfer and otherwise process personal information in strict compliance with applicable PRC laws and regulations of the People’s Republic of China.
Our website may contain links to third party websites for your convenience. We do not control, and are not responsible for, the privacy practices of such third parties. We encourage you to review their privacy policies before using those websites.
If you have any questions or concerns regarding this Policy or our processing of personal information, please contact us using the details provided below.
This Policy will help you understand:
I. How we collect your personal information
II. How we use your personal information
III. How we entrust, share, transfer and publicly disclose your personal information
IV. Cross border transfer of personal information
V. How we store your personal information
VI. Security measures
VII. Your rights
VIII. Personal information of minors
IX. Updates to this Policy
X. How to contact us
I. How do we collect your personal information?
In addition to our employees, we may process personal information of the following persons:
• Visitors and users of our website;
• Healthcare Professionals;
• Investigators of clinical trial institutions and personnel of contract research organizations in clinical trials;
• Subjects of clinical trials and their relatives;
• Consumers/patients and their relatives using our products or services;
• Staff of business partners (including vendors, distributors, partners, etc.); and
• Our applicants.
We may process personal information of website visitors and individuals who contact or interact with us through our website or other online resources. Depending on the relevant page, function, or interaction, separate privacy notices, consents, platform privacy policies, contracts, or other notices may apply.
Based on the context in which you interact with us, we may collect personal information by the following means and on the legal bases permitted by applicable PRC laws and regulations, including your consent, the necessity for entering into or performing a contract, compliance with legal obligations, protection of life, health or property, public health needs, or other circumstances permitted by law:
• Your personal information provided to us voluntarily
When you subscribe to our news or announcements, contact us through the contact details or other interactive features made available on our website, a third-party platform or service linked or referred to on our website, or otherwise communicate with us in relation to our website, we may collect the personal information that you voluntarily provide, such as your name, contact details, organization, and the content of your inquiry or request, depending on the relevant page or function.
• Personal information collected by us independently through our website and other online channels
When you visit our website, most of our services do not require any registration, and you can visit our website without telling us who you are. However, some pages or functions may require you to provide certain personal information. If you choose not provide such information as we request, you may not be able to access certain content or functions or we may not be able to respond to your inquiry, request or subscription. Please refer to the relevant page or notice for further details about the categories of personal information collected in a specific scenario.
• Personal information we collect from vendors or business partners
In the course of our daily business operations, we may collect personal information from our vendors or business partners. We require our vendors and business partners to comply with the requirements of the personal information protection laws and regulations of the PRC and to lawfully provide us with personal information. If you are an employee or representative of one of our vendors or business partners, we may collect personal information such as your name and contact details for the purpose of establishing business contacts and cooperations.
• Personal information we collect from publicly available sources
We may collect personal information of medical and healthcare professionals from such publicy available sources, such as the official websites of medical institutions and the official websites of competent government departments, and process such information within a reasonable scope and for lawful purposes. For example, for the purpose of lawful academic or professional interaction with healthcare professionals, we may collect the name, gender, employer, position, practitioner registration information, academic title, degree, educational background, specialty expertise, and profile information, where such information has been lawfully made public.
Our website may include links, contact details, QR codes, or references to third-party platforms or services. Where you choose to interact with us through such third-party platforms or services, the relevant third party may also process your personal information in accordance with its own privacy policy and applicable law, and we encourage you to review such policy before submitting your information.
II. How do we use your personal information?
We may use your personal information for the following purposes:
• Operating, maintaining and improving our website and other online resource;
• Researching, developing, providing and continuously improving our products and services;
• Conducting and managing daily business;
• Academic interaction with healthcare professionals;
• Responding to your inquiries, requests, or communications sent through our website or the contact details made available on our website;
• Providing subscription services for our news, announcements, or investor-related updates;
• Managing and maintaining our relationship and communications with business contacts who reach us through our website;
• Recruiting and human resource management;
• Internal compliance management，audit，record-keeping; and
• Complying with applicable PRC laws and regulations, for example, monitoring and reporting adverse events for purposes of performing drug quality management responsibilities, providing medical information and dealing with product complaints, etc..
We will process personal information only to the extent necessary for the relevant purpose. Where required by applicable law, we will obtain your consent or separate consent before processing your personal information or sensitive personal information. Where a third-party platform or service is used in connection with a particular function, the relevant third party may process your personal information in accordance with its own privacy policy and applicable law.
III. How do we entrust, share, transfer and publicly disclose your personal information?
1. Entrustment
We may entrust our business partners with the processing of your personal information for the purpose(s) described in this Policy. We will enter into appropriate confidentiality, data processing and security agreements with such entrusted parties and require them to process personal information in accordance with our instructions , this Policy and applicable PRC laws and regulations.
2. Sharing and public disclosure
For the purpose(s) described in this Policy, we will share or publicly disclose your personal information only where permitted by applicable PRC laws and regulations and, where required, after obtaining your consent or separate consent. Such circumstances may include:
• Sharing your personal information among our affiliates and subsidiaries where necessary for legitimate business, management, compliance, or operational purposes;
• Sharing your personal information with vendors or business partners (such as conference service providers, travel service providers, data service providers, banking or insurance institutions, other professional service organizations, to the extent necessary for the relevant purpose); and
• Disclosing your personal information to the extent that it is permitted or required by applicable PRC laws and regulations or for the purpose of assisting with investigations by judicial, regulatory or law enforcement authorities.
• other circumstances permitted by applicable PRC laws and regulations.
If you submit your information through or in connection with a third-party platform or service referred to on our website, the relevant third party may independently process your personal information in accordance with its own privacy policy and applicable law.
3. Transfer
We will not transfer your personal information to any other company, entity or individual unless otherwise permitted by applicable law and, where required, after obtaining your consent. Further, in the event of a merger, acquisition, insolvency, reorganization, division, dissolution, bankruptcy, or similar transaction, we will require the new processor of your personal information to continue to be bound by this Policy or we will require the new processor to obtain your consent again.
IV.How do we provide your personal information across borders?
In principle, personal information that we collect and generate in the course of our operations within the territory of the PRC will be stored within the PRC. In certain circumstances, it may be necessary for us to provide your personal information to recipients outside the PRC in connection with our business operations, website functions, or communications, where permitted by applicable PRC laws and regulations. As required by applicable laws and regulations regarding the protection of personal information, we will provide you with the required notice and obtain your separate consent before providing your personal information across any border, unless otherwise permitted by law. We will use lawful cross-border transfer mechanisms to transfer your personal information oversea and will take necessary measures to ensure that the oversea recipients provide a level of protection required by applicable PRC laws and regulations.
You may obtain more information about cross-border transfers of personal information and oversea recipients through the contact methods referred to in this Policy.
V. How do we store your personal information?
We will retain your personal information for the minimum period necessary to achieve the purposes described in this Policy ,unless a longer retention period is required or permitted by applicable PRC laws and regulations. Upon expiration of the applicable retention period, we will promptly delete or anonymize your personal information in accordance with applicable PRC laws and regulations. Our criteria for determining the period for which personal information shall be retained include:
• Applicable laws, regulations and other relevant requirements;
• The period of time needed for us to provide services, maintain business relations or interact with you; and
• The period of time needed for us to perform relevant agreements or fulfil the purposes described in this Policy.
VI. What security measures do we take to protect your personal information?
In accordance with applicable PRC laws, regulations, and the requirements of relevant national standards, we take reasonable and appropriate security and precautionary measures to protect the personal information we process against unauthorized access, public disclosure, use, modification, destruction or loss of data. However, you are also responsible for taking appropriate measures to protect the security of the devices, systems, and networks you use when accessing our website or communicating with us.
VII. Your rights
In accordance with the requirements of the applicable PRC laws and regulations, you may have the following rights in respect of your personal information:
• To know about and make decisions regarding the processing of your personal information;
• To access or copy your personal information;
• To correct or supplement your personal information;
• To delete your personal information;
• To request for explanation of rules regarding processing of personal information; and
• To change the scope of your consent or revoke your consent , where processing is based on your consent.
If you wish to exercise your rights with respect to personal information, you may contact us through the contact information listed in this Policy and we will respond to any request in accordance with applicable relevant laws and regulations. When you exercise the above rights, we may verify your identity to safeguard the security of your personal information. Subject to applicable PRC laws and regulations, there may be circumstances where we are unable to respond to all or part of your request.
VIII. How do we process the personal information of minors?
For the purposes of this Policy and in accordance with applicable PRC laws and regulations, our products, websites and services are not targeted at minors under the age of 14. Minors under the age of 14 should not provide personal information to us without the consent of a parent or legal guardian.
If a minor's personal information is collected with the consent of a parent or legal guardian, we will process the information only when permitted by law, with the express consent of the parent or legal guardian, or necessary for the protection of the minor. If we discover that we have collected personal information without obtaining verifiable prior consent of a parent or legal guardian, we will seek to delete the data as soon as possible.
IX. Updates of the Policy
We may revise our Privacy Policy from time to time. We will post the updated version on our website and update the “Last Updated” date above or below this Policy.
Last updated: March 30, 2026.
X. How to contact us?
If you have any questions, comments or suggestions concerning this Policy, or any questions or concerns about our processing of your personal information, you may contact us in the following ways:
Address: 11/F, B8 Building, No.188 Yizhou Rd, Xuhui District, Shanghai
Tel.: 021- 33395800
Postal Code: 200233
Email: PR@178xian.com
Cookies Policy
When you visit our website, we may place small data files known as “cookies” on your device. Cookies enable our website to recognize your browser and help us understand how visitors use the site.
Cookies and similar technologies used on this website may collect online identifiers, device information, browser information, IP address, and information about how you interact with the website. In certain circumstances, such information may constitute personal information or may be associated with you under applicable PRC laws and regulations. Information collected through cookies is used for purposes such as ensuring website operation, maintaining security, analyzing traffic and performance, remembering user preferences, and improving website content and user experience.
You may choose to accept or decline cookies by adjusting your browser settings or through any cookie banner or preference center made available on our website, if applicable. Please note that disabling cookies may affect the functionality of certain parts of the website.
For more information about how we process personal information, please refer to our Privacy Notice.
Some cookies may be provided by third parties. Where third-party cookies or similar technologies are used, such third parties may process the relevant information in accordance with their own privacy policies and applicable PRC laws and regulations.
Accessibility
Shanghai Henlius Biotech, Inc. (“Henlius”) is committed to improving the accessibility and user friendliness of its website for all visitors.
We strive to ensure that the content on our website can be accessed and used by individuals with diverse needs, including those who rely on assistive technologies. As our website continues to evolve, we recognize that accessibility is an ongoing effort, and we are continuously working to improve usability and accessibility across our digital platforms.
If you experience difficulty accessing any part of our website, or have suggestions on how we can enhance accessibility, we welcome your feedback. To help us respond effectively, please include the specific webpage address (URL) and a brief description of the issue encountered.
Contact us:
Email: PR@178xian.com
(Please include “Website Accessibility” in the subject line)
Henlius will make reasonable efforts to review accessibility-related feedback and improve the overall online experience for all users. While we strive to improve accessibility, we do not guarantee that every page or feature will be fully accessible to every user in all circumstances.
Terms of Use
This website (http://www.178xian.com/) is developed and operated by Shanghai Henlius Biotech, Inc. (“Henlius”). Please read these Terms of Use carefully before accessing or using this website. By accessing, browsing or using this website, you acknowledge that you have read, understood and agreed to be bound by these Terms of Use and applicable PRC laws and regulations.
Henlius reserves the right to modify or update these Terms of Use at any time. Any updated version will be posted on this website with a revised “Last Updated” date. Please review them periodically for updates.
Prohibited Conduct:
You shall not infringe the lawful rights and interests of Henlius or any third party, nor interfere with or attempt to interfere with the normal operation, security, or integrity of this website by any means. Without limitation, you shall not use this website for any unlawful purpose, attempt unauthorized access to any part of the website or related systems, introduce malicious code, scrape or extract website content through automated means, or otherwise interfere with the website’s operation or security features.
Copyright
All content on this website, including but not limited to text, data, logos, graphics, audio, video and other materials, is owned by Henlius or its respective rights holders, unless otherwise stated. Such content is protected by applicable Chinese and international copyright laws. This website and its content may be accessed and used only for lawful, personal, and non-commercial purposes. Without prior written consent, no entity or individual may copy, reproduce, republish, upload, post, transmit, distribute, modify, create derivative works from, mirror, or otherwise use such content for commercial or public purposes.
Disclaimers
To the fullest extent permitted by applicable PRC laws and regulations, Henlius makes no warranties or representations, express or implied, regarding the content of this website, including but not limited to accuracy, completeness, timeliness or suitability for any particular purpose. Henlius does not undertake any obligation to update the content of this website , except as otherwise required by applicable PRC laws and regulations.
You use this website and any information obtained from it at your own risk. To the fullest extent permitted by applicable PRC laws and regulations, Henlius shall not be liable for any loss or damage arising from the use or inability to use this website, including but not limited to system failures, computer viruses or data loss.
Medical Information
Nothing on this website constitutes medical advice, diagnosisor treatment recommendations. Medical decisions should always be made in consultation with qualified healthcare professionals. Any product-related or disease-related information provided on this website is provided for general informational purposes only and should not be construed as medical advice, diagnosis, or treatment recommendations; any product information is subject to the approved prescribing information and applicable local laws and regulations.
Third Party Websites
This website may contain links to third party websites for convenience. Henlius is not responsible for the content, availability, privacy practices, terms or use of such third-party websites. Access to third party websites is at your own risk.
Privacy
Henlius respects your privacy. Please refer to our Privacy Notice for details.
Governing Law
These Terms of Use shall be governed by the laws of the People’s Republic of China.
Last updated: March 30, 2026
